Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ES014 phase 2 study in adult desmoid tumor
CTR20261226Phase 2Active
- Sponsor
- Elpiscience
- Start
- Apr 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc Fusion Proteins → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ES014 in aggressive fibromatosis (AF), sponsored by Elpiscience. Started Apr 2026; status: active.
02
Drugs
ES014
03
Conditions
aggressive fibromatosis (AF)
Beyond the preview
Go deeper on CTR20261226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261226.